Duloxetine - Eli Lilly

Drug Profile

Duloxetine - Eli Lilly

Alternative Names: Ariclaim; Cymbalta; LY-227942; LY-248686; Xeristar; Yentreve

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Shionogi
  • Class Antidepressants; Naphthalenes; Non-opioid analgesics; Propanolamines; Small molecules; Thiophenes
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Back pain; Depressive disorders; Diabetic neuropathies; Fibromyalgia; Generalised anxiety disorder; Major depressive disorder; Musculoskeletal pain; Neuropathic pain; Stress incontinence
  • Phase II/III Chronic fatigue syndrome

Most Recent Events

  • 05 Feb 2018 Eli Lilly initiates enrolment in a phase III trial for Major depressive disorder in Japan (JapicCTI-183853)
  • 29 Jan 2018 Eli Lilly and Shionogi initiates enrolment in a phase III trial for Major depressive disorder (In adolescents, In children) in Japan (PO) (NCT03395353)
  • 10 Jan 2018 Eli Lilly plans a phase III trial for Major depressive disorder in January 2018 , (NCT03395353)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top